Key result
Fluvastatin lowers LDL-C ~21% but fails to reduce AECG ischemia or post-MI events.
Why the study?
Residual ischaemia following acute myocardial infarction is related to adverse outcomes, but the effect of early statin therapy on ischaemia is unknown.
Does fluvastatin reduce ischemia on AECG or major clinical events in patients following acute myocardial infarction?
RCT (n=540)
Double-blind
Parallel
Does fluvastatin reduce ischemia on AECG or major clinical events in patients following acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
Early initiation of fluvastatin 80 mg daily did not significantly reduce AECG ischemia or major clinical events at 1 year post-AMI, though the study was underpowered due to low baseline ischemia rates.
AIMS: Residual ischaemia following acute myocardial infarction (AMI) is related to an adverse outcome, although the effect of early initiation of statin therapy is unknown. METHODS: A randomized, placebo-controlled, double-blind, parallel study was performed, which compared fluvastatin 80 mg daily with placebo in patients with an AMI and total cholesterol of <6.5 mmol.l(-1). Ischaemia was measured by ambulatory electrocardiographic (AECG) monitoring over 48-h at baseline, after 6 weeks and at 12 months. RESULTS: Five hundred and forty patients were included (83% male, age 61+/-11 years); 43% had an anterior AMI and 50% were treated with fibrinolytics in the acute phase. After 12 months, the total cholesterol (TC) level was reduced by 13% and LDL-C (low-density-lipoprotein cholesterol) by 21% (from 3.5 mmol.l(-1) to 2.7 mmol.l(-1)) in the fluvastatin treatment group. Both TC and LDL increased by 9% in the placebo group (P<0.001 between groups). At baseline, ischaemia on AECG was present in only 11% of patients, and absent in 77%; in the remaining 11%, recordings were technically inadequate. After 6 weeks, 32/48 (67%), and 12 months 35/46 (76%) of the patients with ischaemia on the baseline AECG, no longer showed signs of ischaemia. Nevertheless, ischaemia at baseline was predictive for the occurrence of any major clinical event (RR=2.35; 95% CI 1.39-3.2;P <0.001). Fluvastatin treatment did not affect ischaemia on AECG, nor the occurrence of any major clinical events as compared to placebo. Post-hoc analysis in patients with the most pronounced ischaemia at baseline showed a trend for a beneficial effect of fluvastatin on major clinical events (P=0.084). CONCLUSION: Residual ischaemia after AMI is observed less frequently in the present study, than in earlier studies, although it is predictive for future cardiovascular events. As a result, the present study was underpowered, and no effect of fluvastatin on AECG ischaemia, or major clinical events in the first year after AMI, could be detected. The present data do not confirm other reports which support widespread use of statin treatment early after AMI.
No takes yet. Share an insight, caveat, or question.
An Ho Liem (2002) conducted an RCT in Acute myocardial infarction (AMI) (n=540). Fluvastatin vs. Placebo was evaluated on Ischaemia on ambulatory electrocardiographic (AECG) monitoring and major clinical events. Fluvastatin daily reduced LDL-C by 21% but did not affect AECG ischaemia or major clinical events in the first year after acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: